Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Tg Therapeutics (TGTX) over the last 9 years, with Q1 2024 value amounting to $146.2 million.

  • Tg Therapeutics' Shares Outstanding (Weighted Average) rose 420.27% to $146.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $146.2 million, marking a year-over-year increase of 420.27%. This contributed to the annual value of $135.4 million for FY2022, which is 241.15% up from last year.
  • As of Q1 2024, Tg Therapeutics' Shares Outstanding (Weighted Average) stood at $146.2 million, which was up 420.27% from $141.5 million recorded in Q2 2023.
  • Tg Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $146.2 million during Q1 2024, with a 5-year trough of $105.5 million in Q1 2020.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $129.9 million, with a median of $132.4 million in 2021.
  • Per our database at Business Quant, Tg Therapeutics' Shares Outstanding (Weighted Average) soared by 3290.85% in 2020 and then soared by 189.68% in 2022.
  • Tg Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $115.3 million in 2020, then grew by 14.64% to $132.2 million in 2021, then rose by 2.41% to $135.4 million in 2022, then grew by 4.5% to $141.5 million in 2023, then grew by 3.33% to $146.2 million in 2024.
  • Its Shares Outstanding (Weighted Average) was $146.2 million in Q1 2024, compared to $141.5 million in Q2 2023 and $140.3 million in Q1 2023.